Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR3 | P29371 | 20/20 | 0.54 |
| ▸ | TACR2 | P21452 | 8/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | TACR1 | P25103 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4665726 | 0.91 | TACR3 (0.56) | TACR3TACR2OPRM1CYP1A2CYP3A4 | |
| SCHEMBL4667050 | 0.90 | TACR3 (0.55) | TACR3TACR2OPRM1CYP1A2CYP3A4 | |
| SCHEMBL4667100 | 0.90 | TACR3 (0.68) | TACR3TACR2OPRM1CYP1A2CYP3A4 | |
| SCHEMBL4667065 | 0.88 | TACR3 (0.53) | TACR3TACR2OPRM1CYP1A2CYP3A4 | |
| SCHEMBL5001051 | 0.86 | TACR3 (0.57) | TACR3TACR2OPRM1 | |
| SCHEMBL4665874 | 0.83 | TACR3 (0.61) | TACR3TACR2CYP2C9 | |
| SCHEMBL5004662 | 0.83 | TACR3 (0.54) | TACR3TACR2OPRM1CYP1A2CYP3A4 | |
| SCHEMBL5001041 | 0.83 | TACR3 (0.62) | TACR3TACR2OPRM1 | |
| SCHEMBL13995504 | 0.82 | TACR3 (0.78) | TACR3TACR2OPRM1CYP1A2CYP3A4 | |
| SCHEMBL5001148 | 0.81 | TACR3 (0.73) | TACR3TACR2OPRM1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080234269-A1 | N-Oxo-Heterocycle and N-Oxo-Alkyl Quinoline-4-Carboxamides as Nk-3 Receptor Ligands | ASTRAZENECA AB (SE) | 2008-09-25 | — | — | US | claimed |
| US-20080234269-A1 | N-Oxo-Heterocycle and N-Oxo-Alkyl Quinoline-4-Carboxamides as Nk-3 Receptor Ligands | ASTRAZENECA AB (SE) | 2008-09-25 | — | — | US | disclosed |
| US-20080234269-A1 | N-Oxo-Heterocycle and N-Oxo-Alkyl Quinoline-4-Carboxamides as Nk-3 Receptor Ligands | ASTRAZENECA AB (SE) | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234269-A1 | N-Oxo-Heterocycle and N-Oxo-Alkyl Quinoline-4-Carboxamides as Nk-3 Receptor Ligands | TACR3, TACR2, KCNA3 | TACR3 1/4885TACR2 2/4885OPRM1 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.